July 01, 2022
Patients with stage IB to IIA non–small cell lung cancer who experienced a pathologic complete response to neoadjuvant nivolumab plus platinum-based doublet chemotherapy experienced a prolonged event-free survival.
June 05, 2022
Patritumab deruxtecan induced positive efficacy, according to the phase 1/2 U31402-J101 trial in patients with HER3-expressing metastatic breast cancer or metastatic triple-negative breast cancer.
May 27, 2022
Non-White Hispanic pediatric patients with neuroblastoma appear to have worse overall survival outcomes vs other patient subgroups.
April 25, 2022
The phase 2 KarMMA trial showed that certain characteristics were potentially linked to complete responses in patients with multiple myeloma.
April 24, 2022
A phase 2 trial reported a reduction in steroid-refractory chronic graft versus host disease and prednisone use following treatment with abatacept after stem cell transplant.
April 12, 2022
Patients with metastatic castration-resistant prostate cancer who had a high genomic loss of heterozygosity may respond better to treatment with talazoparib.
April 10, 2022
Investigators of a phase 1/2 trial observed positive response outcomes with expanded natural killer cells plus AMF13 in patients with heavily pretreated lymphoma.
April 09, 2022
Early findings from the phase 1/2a TEM-GBM study presented at the 2022 AACR Annual Meeting displayed potential of temferon to affect the tumor microenvironment of glioblastoma.
March 19, 2022
Patients with BRCA-mutant, homologous repair deficiency–positive advanced resectable ovarian cancer may benefit from treatment with neoadjuvant niraparib, according to early results of a phase 2 trial reported at 2022 SGO.
March 18, 2022
The phase 2 CC-ANNIE trial was launched in China investigating anlotinib plus sintilimiab for recurrent platinum-resistant ovarian clear cell carcinoma.